B. Riley analyst Kyle Bauser raised the firm’s price target on ClearPoint Neuro (CLPT) to $15 from $14 and keeps a Buy rating on the shares following the Q3 report. The firm sees continued momentum across the company’s diversified business.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks